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Objectives The aim of this study was to derive and validate a model to predict survival in candidates for HeartMate II (HMII)
(Thoratec, Pleasanton, California) left ventricular assist device (LVAD) support.
Background LVAD mortality risk prediction is important for candidate selection and communicating expectations to patients
and clinicians. With the evolution of LVAD support, prior risk prediction models have become less valid.
Methods Patients enrolled into the HMII bridge to transplantation and destination therapy trials (N  1,122) were ran-
domly divided into derivation (DC) (n  583) and validation cohorts (VC) (n  539). Pre-operative candidate pre-
dictors of 90-day mortality were examined in the DC with logistic regression, from which the HMII Risk Score
(HMRS) was derived. The HMRS was then applied to the VC.
Results There were 149 (13%) deaths within 90 days. In the DC, mortality (n  80) was higher in older patients (odds
ratio [OR]: 1.3, 95% confidence interval [CI]: 1.1 to 1.7 per 10 years), those with greater hypoalbuminemia (OR:
0.49, 95% CI: 0.31 to 0.76 per mg/dl of albumin), renal dysfunction (OR: 2.1, 95% CI: 1.4 to 3.2 per mg/dl cre-
atinine), coagulopathy (OR: 3.1, 95% CI: 1.7 to 5.8 per international normalized ratio unit), and in those receiv-
ing LVAD support at less experienced centers (OR: 2.2, 95% CI: 1.2 to 4.4 for 15 trial patients). Mortality in the
DC low, medium, and high HMRS groups was 4%, 16%, and 29%, respectively (p  0.001). In the VC, corre-
sponding mortality was 8%, 11%, and 25%, respectively (p  0.001). HMRS discrimination was good (area un-
der the receiver-operating characteristic curve: 0.71, 95% CI: 0.66 to 0.75).
Conclusions The HMRS might be useful for mortality risk stratification in HMII candidates and may serve as an addi-
tional tool in the patient selection process. (J Am Coll Cardiol 2013;61:313–21) © 2013 by the American
College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.09.055Left ventricular assist device (LVAD) support is increas-
ingly being used for patients with refractory heart failure as
either a bridge to transplantation (BTT) or destination
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012, accepted September 29, 2012.therapy (DT). Through June 2012, over 4,000 LVAD
implants have been reported to the U.S. INTERMACS
(Interagency Registry for Mechanically Assisted Circula-
tory Support) (1), and it is estimated that 30,000 to
100,000 individuals annually in the United States could
potentially benefit from LVAD support. With so many
patients potentially in need of a device that carries (simul-
taneously) associated medical and societal benefits and
burdens, careful patient selection is paramount.
See page 322
In a young and evolving field such as mechanical circu-
latory support (MCS), risk modeling for the purposes of
LVAD patient selection and patient and family education is
in a constant state of revision. Increasing clinical experience,
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and information gleaned from
studies on patient selection (2–4),
as well as pre- and post-operative
management strategies have led to
improvements in patient survival
from 52% at 1 year on pulsatile
LVAD support (5) to 85% for
BTT patients (6), and 73% for
DT patients (7) supported with
continuous flow LVAD technol-
ogy. At present, the destination
therapy risk score (DTRS) and
INTERMACS profiles are the
most widely used LVAD risk pre-
diction tools (2). Derived in the
pulsatile LVAD era, the DTRS
was recently shown to provide
poor discrimination for BTT pa-
tients and only modest discrimina-
tion for DT patients supported
with continuous flow LVADs (8).
However, the utility of both tools
for assessing LVAD candidate risk
in the contemporary LVAD era is
in question, and a reassessment and revision of LVAD candi-
date risk prediction is warranted.
The primary objective of this analysis was to develop and
validate a risk model for predicting LVAD candidate
outcome in the “continuous flow era” of MCS. The second
objective was to identify predictors of longer-term survival,
independent of LVAD operative success.
Methods
Patient cohort. Patients enrolled between March 2005 and
January 2010 into either the HeartMate II (HMII) (Tho-
ratec, Pleasanton, California) BTT or DT clinical trials who
received a HMII LVAD (N  1,122) were selected for this
tudy. Both HMII trials were prospective multicenter stud-
es designed to assess the morbidity and mortality of subjects
ith end-stage heart failure undergoing implantable
VADs for long-term MCS. Details of the design, meth-
ds, and results of both the BTT (9,10) and DT trials (11)
ave been previously reported. Patients receiving the HMII for
ompassionate use or as an exchange for a previous HeartMate
VE were excluded. All patients provided written informed
onsent before study participation, and local institutional re-
iew board approval was provided by all enrolling centers.
tatistical analysis. DESCRIPTIVE STATISTICS. Data analy-
is was performed with SAS (version 9.2, Cary, North
arolina). Continuous data were evaluated for normality,
nd accordingly, between-group comparisons with Student
or Mann-Whitney testing were performed. Categorical
Abbreviations
and Acronyms
AUC  area under the
receiver-operating
characteristic curve
BTT  bridge to transplant
DT  destination therapy
DTRS  destination
therapy risk score
HMII  HeartMate II
HMRS  HeartMate II risk
score
IABP  intra-aortic balloon
pump
INR  international
normalized ratio
LVAD  left ventricular
assist device
MCS  mechanical
circulatory support
MELD  model for end-
stage liver disease
RA  right atrium/atrialata were compared with Fisher exact test.DERIVATION AND VALIDATION OF THE HMII RISK
SCORE. HMII patients enrolled into both trials were con-
solidated and then randomly divided into derivation
(n  583) and validation (n  539) cohorts. The derivation
cohort was used to develop a model for calculation of a
patient-specific risk estimate, termed the HeartMate II Risk
Score (HMRS), for predicting LVAD candidate 90-day
mortality. Unadjusted predictors of mortality were identified
from logistic regression comparisons of baseline clinical (pa-
tient demographic data, body mass index, heart failure etiology,
pre-operative vasopressor and inotrope use), pre-operative
laboratory (white blood count, hematocrit, platelet count,
serum sodium, blood urea nitrogen, creatinine, total bilirubin,
albumin, protein, alanine and aspartate aminotransferase, in-
ternational normalization ratio [regardless of warfarin use]),
and cardiopulmonary hemodynamic data (right atrial [RA]
pressure, pulmonary artery pressures, cardiac index, pulmonary
vascular resistance). Hemodynamic and laboratory measures
were obtained 48 h before LVAD implant.
Clinically relevant risk correlates from prior LVAD risk
modeling studies (age, sex, DT indication, pre-operative
ventilator and/or intra-aortic balloon pump (IABP) sup-
port, pre-operative vasodilator, vasopressor and/or inotrope
support, platelet count, total bilirubin, aspartate amino-
transferase, blood urea nitrogen, serum creatinine, hemato-
crit, international normalized ratio [INR], albumin, mean
pulmonary artery pressure, RA pressure, and right ventric-
ular stroke work index, and implanting center LVAD study
volume) (1–3,12,13) were then manually entered into step-
wise multivariable logistic analysis (exit criteria p  0.05).
Correlated variables (e.g., RA pressure and right ventricular
stroke work index) were not entered simultaneously, and only
8 to 10 variables were entered at one time to avoid model
“overfitting.” Center volume was defined as the volume of
LVADs implanted by the center of study during the entire
HeartMate BTT or DT study period. To determine center
volume thresholds, patients were first dichotomized at the
10th, 15th, 20th, and 25th percentiles on the basis of the total
volume of HMIIs implanted at the study center. The dichot-
omization threshold was selected as the smallest percentile
value for center volume at which statistically significant differ-
ences in survival were observed. This was also the center
volume demonstrated to be of importance by Lietz et al. (13).
Model discrimination and calibration was evaluated with the
area under the receiver-operating characteristic curve (AUC)
and Hosmer-Lemeshow goodness of fit tests, respectively.
The continuous HMRS was first dichotomized into
deciles of risk in order to derive the low, medium, and high
HRMS categories. The deciles were then examined and
consolidated into 3 risk categories (low [10% mortality],
medium [10% to 20% mortality], and high risk [20%
mortality]) offering clinically relevant risk estimates of
90-day mortality with good discrimination. LVAD survival
on the basis of HMRS category was assessed in the
derivation and validation cohorts by evaluating the propor-
tion of patients alive at 90 days post-LVAD implant
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recovery). Survival differences between the 3 groups were
compared with the Pearson chi-square test. When signifi-
cant differences between groups were observed, post hoc
comparisons were performed with the Fisher exact test. To
avoid bias in model development, the validation cohort was
only analyzed after the risk model was derived.
COMPARISON OF HMRS WITH DTRS AND MODEL FOR END-
STAGE LIVER DISEASE. The HMRS was compared with
pre-operative DTRS (8) and the United Network for Organ
Sharing–modified model for end-stage liver disease
(MELD) scores that has recently been shown to be predic-
tive of survival in LVAD patients (3). Receiver-operating
characteristic curves for predicting 90-day survival on the
basis of HMRS, DTRS, and MELD were generated for the
total study cohort. The AUCs were calculated and com-
pared between HMRS and DTRS as well as HMRS and
MELD with the methodology described by DeLong et al.
in SAS (14).
Predictors of long-term survival. Long-term survival on
the basis of HMRS category was estimated with Kaplan-
Meier methods, and survival was compared with log-rank
Baseline Characteristics of PatientsR ndomized Into the Derivation a d Validation CTable 1 B selin Char cteristics of P ie tRandomized Into the Derivation and
Derivatio
(n 
Demographic data
Age, yrs 58.9
Female 133 (23
Ischemic etiology 315 (54
NYHA functional class
IIIb 158 (27
IV 425 (73
Length of support, days* 347 (11
Concomitant procedure 235 (40
Bypass time, min 107
Caucasian race 433 (74
LVAD indication
Destination therapy 338 (58
Bridge to transplant 245 (42
Implant after May 5, 2007 331 (57
Center volume 15 508 (87
Laboratory values
Sodium, mg/dl 134.3
Creatinine, mg/dl 1.47
Aspartate aminotransferase, IU/l 54
Total bilirubin, mg/dl 1.22
Hematocrit, % 34.8
Albumin, g/dl 3.44
Platelets, K/m3 212
INR 1.31
Medications
Intravenous inotrope 495 (85
Intravenous vasodilator 155 (27
Values are n (%), mean  SD, or median (25th–75th percentile).
CI  confidence interval; HR  hazard ratio; INR  international normalize
Association functional class.testing. Cox proportional hazards modeling was then used
to identify correlates of long-term survival in patients who
survived the initial 90-day post-operative period.
Results
Characteristics of the derivation and validation cohorts.
The derivation and validation cohorts were similar with regard
to baseline demographic data, pre-operative hemodynamic
status, laboratory values, and medication use (Table 1). Median
LVAD support durations were 347 and 332 days in the
derivation cohort and validation cohort, respectively (p 
0.84), and Kaplan-Meier survivals were similar (p  0.84)
Fig. 1).
orrelates of mortality after LVAD implant. There were
0 deaths (14%) in the derivation cohort (n  583) during
he 90-day post-operative period. Expired patients tended
o be older, had greater degrees of hypoalbuminemia,
oagulopathy (higher INR), and poorer renal function
higher creatinine) (see Table 2; complete listing available in
he Online Table). Pre-operative warfarin was used in only
9 patients and was not correlated with survival, suggesting
hat a higher INR was a risk factor for mortality irrespective
ts
dation Cohorts
ort Validation Cohort
(n  539) p Value
58.2 14.2 0.57
117 (22%) 0.67
283 (53%) 0.61
0.12
124 (23%)
415 (77%)
) 332 (117–727) 0.84
228 (42%) 0.51
109 58 0.25
391 (73%) 0.54
0.28
295 (55%)
244 (45%)
309 (57%) 0.86
485 (90%) 0.16
134.4 4.7 0.88
1.46 0.54 0.89
64 190 0.97
1.24 0.90 0.60
34.9 5.6 0.45
3.52 1.21 0.14
221 86 0.02
1.36 0.60 0.82
426 (79%) 0.01
157 (29%) 0.35ohors
Vali
n Coh
583)
13.3
%)
%)
%)
%)
1–656
%)
63
%)
%)
%)
%)
%)
4.7
0.55
137
0.80
5.6
0.58
87
0.33
%)
%)d ratio; LVAD  left ventricular assist device; NYHA  New York Heart
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90-day survival. Centers that had implanted 15 or more
HMIIs during the trial periods (89% of centers) had
significantly better outcomes than centers that implanted
15 patients over the course of the trial.
On multivariable analysis, age, serum creatinine, albumin,
INR, and LVAD implanting center volume correlated with
overall survival during LVAD support (Table 3). Pre-
operative IABP and ventilator support and vasoactive med-
ication requirements were not associated with worse out-
come. LVAD indication (BTT vs. DT) was also not
predictive of outcome in the multivariable model (see
footnote of Table 3 for covariates entered into the model).
The HMRS and post-operative outcomes in derivation
cohort. With logistic regression estimates for 90-day
survival, a patient pre-operative HMRS was derived as
shown in Table 3. The median (25th to 75th percentile)
HMRS for the derivation cohort was 1.75 (1.18 to 2.36).
Survivors had lower HMRS scores (1.68 [1.13 to 2.19])
than patients who died (2.37 [1.95 to 3.09], p  0.001).
The HMRS AUC (95% confidence interval [CI]) was 0.77
Figure 1 Survival and Hazard Rate for
the Derivation and Validation Cohorts
A comparison of Kaplan-Meier survival (A) and hazard rates (B) for
the two HeartMate II (Thoratec, Pleasanton, California) cohorts is shown.(95% CI: 0.72 to 0.82), and the Hosmer-Lemeshow good- oness of fit test chi-square was 9.97 (p  0.27), suggesting
good discrimination and calibration, respectively.
The HMRS score cutoffs for the 3 risk groups were: low
risk (HRMS 1.58), medium risk (1.58 HMRS 2.48),
and high risk (HMRS 2.48). Ninety-day mortality in
these 3 groups was 4%, 16%, and 29%, respectively (p 
0.001) (Fig. 2). Pair-wise comparisons showed that both the
high- and medium-risk groups had significantly worse
outcome than the low-risk group (p  0.001).
Validation of the HMRS. The median (25th to 75th
percentile) HMRS in the validation cohort was 1.71 (1.10
to 2.31) and was similar to that of the derivation cohort
(p  0.27). Like the derivation cohort, survivors in the
validation cohort had significantly lower HMRS than deaths
(HMRS: 1.66 [25th, 75th percentile: 1.05 to 2.25] vs. HMRS:
2.11 [1.47 to 2.74], p  0.001). The 90-day mortality for the
low-, medium-, and high-risk HMRS groups was 8%, 11%,
and 25%, respectively (p  0.001) (Fig. 2). Patients in the
validation cohort high-risk HRMS group also had significantly
worse outcome than both low- (p  0.001) and medium-risk
(p  0.002) groups. However, comparison of outcome for
patients within the low- versus medium-risk group did
not reach statistical significance (p  0.25). The
Hosmer-Lemeshow chi-square in the validation cohort
was 1.04 (p  0.31).
HMRS versus DTRS and MELD and by device
indication. Receiver-operating characteristic curves repre-
senting the ability of the HMRS, DTRS, and MELD
scores to predict 90-day mortality in the total HMII sample
(derivation  validation) are shown in Figure 3. Table 4
lists the model AUCs in various patient samples (the total
cohort, the derivation/validation cohorts, and the BTT/DT
cohorts). The HMRS provided significantly higher risk
discrimination than the DTRS when evaluated in the total
HMII sample (p 0.001). When evaluated by device intent
(BTT vs. DT), the HMRS was also more discriminative
than the DTRS (p  0.05). The HMRS had a numerically
higher AUC than the MELD, but statistically significant
differences were only noted in the derivation cohort and the
entire HMII sample.
Long-term survival after LVAD implant. Figure 4 shows
the Kaplan-Meier survival curves for the total HMII sample
stratified by HMRS categories. Survivals at 1 year in the low-,
medium-, and high-risk groups were 83  2%, 72  2%, and
58  3%, respectively (p  0.001) (Table 5). Pair-wise
comparisons revealed that there were significant differences
between the low- versus medium- (p  0.001), low- versus
igh- (p 0.001), and medium- versus high-risk (p 0.001)
roups, suggesting that the HMRS also provides discrim-
nation of risk several months after LVAD implant. As
hown in Figure 5, HMRS risk discrimination is main-
ained regardless of initial device indication (i.e., BTT or
T).
onditional survival. When conditioned on surviving 90
ays postoperative, the only statistically significant pre-
perative predictors of long-term mortality in the derivation
 intra
ndex.
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1.5]/10 years, p  0.003) and center implant volume 15
(hazard ratio: 1.6 [95% CI: 1.0 to 2.6]). Upon adjustment
for age and center volume, mortality in BTT versus DT
patients who survived the 90-day post-operative period was
similar (hazard ratio: 1.1 [95% CI: 0.7 to 1.7] p  0.74).
Univariable Correlates of 90-Day Mortality in theTable 2 Univariable Correlates of 90-Day M
Alive (n  503)
Demographic data
Age, yrs 58.1 13.7
Female 122 (92%)
Male 381 (85%)
Ischemic cardiomyopathy 261 (83%)
Nonischemic cardiomyopathy 242 (90%)
Preoperative ventilator support 23 (85%)
No ventilator support 480 (86%)
Preoperative IABP 154 (87%)
No IABP 349 (86%)
Race
Caucasian (vs. rest) 366 (84%)
Black (vs. rest) 96 (90%)
Other (vs. rest) 41 (95%)
LVAD indication
Destination therapy 283 (84%)
Bridge to transplant 220 (90%)
Implant era
After May 5, 2007 285 (86%)
Before May 5, 2007 218 (87%)
Center volume, n
15 59 (79%)
15 444 (87%)
Hemodynamic status
Right atrial pressure, mm Hg 12.2 6.3
PA systolic, mm Hg 51.7 13.8
Wedge pressure, mm Hg 24.3 8.5
Cardiac index, l/min/m2 2.01 0.60
RVSWi, mm Hg ml/m2 544 282
Laboratory values
Sodium, mg/dl 134 5
Creatinine, mg/dl 1.44 0.54
Blood urea nitrogen, mg/dl 27 (19–40)
Aspartate aminotransferase, IU/l 30 (23–44)
Total bilirubin, mg/dl 1.2 0.8
Albumin, g/dl 3.47 0.58
Hematocrit, % 35.0 5.6
Platelets, K/mm3 214 88
INR 1.29 0.31
Intravenous medications
Inotropes 424 (86%)
No inotropes 79 (90%)
Vasodilator 134 (86%)
No vasodilator 369 (86%)
Vasopressor 22 (81%)
No vasopressor 481 (87%)
Values are mean  SD, n (%), or median (25th–75th percentile). *Fo
CI confidence interval; INR international normalized ratio; IABP
ratio; PA  pulmonary artery; RVSWi  right ventricular stroke work iLikewise, when the entire HMII sample was analyzed,conditional survival was similar in BTT and DT patients
(Fig. 6).
Discussion
In this study, we developed and prospectively validated the
ivation Cohortty in the Derivation Cohort
ad (n  80) p Value* OR (95% CI)
3.6 9.6 0.001 1.45 (1.17–1.80)/10 yrs
11 (8%) 0.041 0.50 (0.26–0.97)
69 (15%)
54 (17%) 0.010 1.93 (1.17–3.17)
26 (10%)
4 (15%) 0.87
76 (14%)
23 (15%) 0.73
57 (14%)
67 (16%) 0.040 1.93 (1.2–2.5)
11 (10%) 0.26
2 (5%) 0.091 0.29 (0.07–1.22)
55 (16%) 0.037 1.71 (1.03–2.83)
25 (10%)
46 (14%) 0.89
34 (13%)
16 (21%) 0.043 1.88 (1.02–3.47)
64 (13%)
4.9 7.3 0.001 1.06 (1.03–1.10)
3.6 13.2 0.26
5.9 8.1 0.16
.15 0.63 0.066 1.43 (0.98–2.08)
527 299 0.64
134 5 0.60
.70 0.56 0.001 2.20 (1.48–3.27)
34 (23–47) 0.024 1.01 (1.00–1.02)
28 (22–39) 0.13
1.3 0.7 0.58
.23 0.56 0.001 0.49 (0.32–0.75)
3.0 5.0 0.003 0.93 (0.89–0.98)
199 79 0.160
.46 0.41 0.001 3.36 (1.84–6.14)
71 (14%) 0.30
9 (10%)
21 (14%) 0.94
59 (14%)
5 (19%) 0.46
75 (13%)
rison of alive versus dead at 90 days.
-aortic balloon pump; LVAD left ventricular assist device; OR oddsDerortali
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dataset. The HMRS components—age, serum albumin,
creatinine, INR, and implant center LVAD experience—
highlight important pre-operative determinants of survival
after LVAD implantation in patients for whom LVAD
support is being considered. Benefits of the HMRS include
its ease of calculation (4 variables) with relatively noninva-
sive, routinely obtained, and reproducible clinical data
points. Furthermore, because device indication (i.e., BTT
vs. DT) is often difficult to predict in the pre-operative
period, the HMRS allows risk prediction in undifferentiated
LVAD candidates.
Benefits of a new LVAD risk model. Current models for
predicting LVAD candidate survival after surgery were
largely derived from patients implanted with older-
Multivariable Predictors of90-Day Mortality in DerivationCohort and Formula f r C lculating HMRS
Table 3
Multiv riable Predictors of
90-Day Mortality in Derivation
Cohort and Formula for Calculating HMRS
Parameter Estimate SE OR (95% CI) p Value
Age (per 10 yrs) 0.274 0.12 1.32 (1.05–1.65) 0.018
Albumin (per g/dl) 0.723 0.23 0.49 (0.31–0.76) 0.002
Creatinine (per mg/dl) 0.740 0.22 2.10 (1.37–3.21) 0.001
INR (per unit) 1.136 0.32 3.11 (1.66–5.84) 0.001
Center volume 15 0.807 0.34 2.24 (1.15–4.37) 0.018
Multivariable predictors (p 0.05) of 90-day mortality in the derivation cohort and the formula for
calculating the HeartMate II Risk Score (HMRS). Calculation of HMRS: HMRS  (0.0274  [age in
ears])  (0.723  [albumin g/dl])  (0.74  [creatinine mg/dl])  (1.136  [INR])  (0.807 
[center LVAD volume 15*]). *Enter value of 1 if total center LVAD volume is 15 and 0 if 15.
Other variables entered into multivariable analysis (all p  0.05 in final model): sex, LVAD
indication, pre-operative inotrope, vasopressor and/or vasodilator use, pre-operative ventilator
support and/or IABP support, RVSWi, hematocrit, platelets, aspartate aminotransferase, total
bilirubin, and implant era. Model fit was inferior when blood urea nitrogen was entered in place of
creatinine into the aforementioned model. Likewise, entering right atrial pressure and/or mean
pulmonary artery pressure in place of RVSWi did not improve modeling.
Abbreviations as in Tables 1 and 2.
Figure 2 90-Day Mortality on the Basis of HMRS
Ninety-day mortalities for the validation and derivation cohorts are shown, stratifie
AUC  area under receiver-operating characteristic curve.generation pulsatile devices (2,4,12). At present, the DTRS
is the most commonly applied LVAD risk prediction tool
(2). The DTRS was derived from patients in the HeartMate
XVE post-REMATCH (Randomized Evaluation of Me-
chanical Assistance for the Treatment of Congestive Heart
Failure) experience (2) and was originally intended to
estimate patient risk for 90-day in-hospital mortality after
LVAD implant. The DTRS is limited by its complexity
(9 variables with a requirement for pulmonary catheter
measurement), the categorization of continuous variables,
eartMate II Risk Score (HMRS) group.
Figure 3 ROC Curves for Predicting 90-Day Mortality
Receiver-operating characteristics (ROC) curves for predicting 90-day mortality
in the entire HeartMate II patient sample using the HeartMate II Risk Score
(HMRS), model for end-stage liver disease (MELD), and destination therapy risk
score (DTRS) are displayed. Area [95% confidence interval] is shown. The ROC p
values: HMRS versus MELD, p  0.022; and HMRS versus DTRS, p  0.001.d by H
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January 22, 2013:313–21 The HeartMate II Risk Score and LVAD Survivaland derivation from a patient cohort supported with a
now-antiquated pump that was associated with a signifi-
cantly higher morbidity and mortality than that of contin-
uous flow technology. Furthermore, the DTRS excluded
BTT candidates in model development and did not include
validation with multicenter data. When the DTRS was
applied to the HMII BTT and DT clinical trial data by
Teuteberg et al. (8), the DTRS was poorly discriminative of
in-hospital 90-day survival (AUC  0.59). A single-center
nalysis by Schaffer et al. (15) also identified similar defi-
iencies in the DTRS for predicting outcome in candidates
or continuous flow LVAD support. By contrast, we have
hown that the HMRS offers improved risk discrimination
ompared with the DTRS, regardless of device indication
DT or BTT).
The INTERMACS levels have been shown to provide
seful categorization of patient risk solely on the basis of
ubjective descriptions of clinical status (16,17). Boyle et al.
16) in a 3-center study demonstrated that patients present-
ng with INTERMACS Level 1 and Levels 2 to 3 had
urvival rates of 51% and 69% at 36 months post-LVAD,
espectively, compared with 95% in Profiles 4 to 7. Al-
Figure 4 Kaplan-Meier Survival Stratified by HMRS Group
Survival for the entire HeartMate II patient sample is shown on the basis of Heart-
Mate II Risk Score (HMRS) group. The vertical lines on the curves correspond to
the 90-day time-point at which the risk model was derived. BTT  bridge to trans-
plant; DT  destination therapy.
Comparisons of AUCs Between Different Risk Models Used to PredTable 4 Comparisons of AUCs Between Different Risk Models
All Patients
(N  1,122)
Derivation Cohort
(n  583)
HMRS 0.71 (0.66–0.75) 0.77 (0.72–0.82)
MELD 0.66 (0.61–0.70)* 0.70 (0.64–0.76)*
DTRS 0.60 (0.54–0.65)† 0.60 (0.53–0.67)†
DTRS‡ 0.57 (0.52–0.63) —
*p  0.05; †p  0.001 compared with HMRS; ‡area under the receiver-operating curve (AUC) re
BTT  bridge to transplant; CI  confidence interval; DT  destination therapy; DTRS  destinchough INTERMACS Level 1 (cardiogenic shock) used to
omprise 44% of LVAD implants (18), findings of poor
utcomes in these patients along with an improvement in
CS technology have led to a shift to slightly earlier
mplantation strategies, such that INTERMACS Level 1
ow only comprises 14% of patient profiles at implant (1).
evels 4 to 7 are highly subjective in assignment, are not
ssigned with concrete patient-level data, and have never
een shown to demonstrate graded mortality risk. The
NTERMACS profiles were not included in the HMII
linical trials herein and could not be included in this
nalysis. However, the objective nature of the HMRS might
ffer risk stratification within and across INTERMACS
rofiles. In this analysis, we included important correlates of
NTERMACS Level 1 status, including pre-operative va-
opressor, inotrope, IABP, and ventilator use. That these
ata did not contribute additional information to the HMRS
uggests that preserved end-organ function, however preoper-
tively achieved, might be the most important predictor of
uccessful LVAD outcome. The HMRS will also take into
ccount the added independent risk of mortality in the elderly
hat is not captured in INTERMACS.
Finally, MELD scores have also been shown to be
redictive of mortality in LVAD candidates, and this model
erformed quite well in this analysis for predicting mortality
n HMII patients (3,19). Although the HMRS and MELD
omprise similar variables, the coefficients used for MELD
core calculation were derived from patients with multifac-
orial liver disease and no documented cardiac dysfunction.
y contrast, HMRS is derived solely from patients with
dvanced heart failure and takes into account the impact of
ge and center experience on surgical outcome. By receiver-
perating characteristic curve analysis, the HMRS provided
better discrimination of outcomes compared with MELD
r DTRS.
ses for the HMRS. In a field with a potential for high
atient morbidity and mortality, high resource use in “non-
hrivers,” and a large pool of medically diverse candidates,
areful patient selection is critical. The HMRS is not meant
o supplant or supersede clinical judgment, nor does it
rovide recommendation whether or not to proceed with
VAD implant. However, the HMRS can provide addi-
ional knowledge of patient risk to help in education and
0-Day Mortalityto Predict 90-Day Mortality
AUC (95% CI)
alidation Cohort
(n  539)
BTT Cohort
(n  489)
DT Cohort
(n  633)
.64 (0.56–0.71) 0.71 (0.63–0.80) 0.68 (0.63–0.74)
.61 (0.53–0.71) 0.67 (0.59–0.76) 0.64 (0.58–0.70)
.59 (0.51–0.67) 0.56 (0.47–0.65)† 0.61 (0.55–0.67)*
— 0.54 (0.45–0.64) 0.58 (0.52–0.57)
n the paper by Teuteberg et al. (8) for predicting 90-day in-hospital mortality.
erapy risk score; HMRS  HeartMate II risk score; MELD  model for end-stage liver disease.ict 9Used
V
0
0
0ommunication with referring cardiologists, patients, fami-
Values are median (25th–75th percentile) or mean  SD.
HMII  HeartMate II; HMRS  HeartMate II risk score; LVAD  left ventricular assist device.
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highlight important goals for pre-operative optimization
and identify a period of optimal patient “fitness” for surgery.
All HMRS variables except for age are potentially modifi-
able. Targeted reduction in patient operative risk through
use of pre-operative percutaneous mechanical support tech-
nologies; inotropes; and/or diuresis to amend renal (serum
creatinine), hepatic/right ventricular dysfunction (INR),
and inflammatory/nutritional states (albumin) might afford
better outcomes. Users of the HRMS should take into
account that INR values used in this study were largely
measured in absence of warfarin use.
LVAD risk modeling is also an important tool for the
principle of “patient-centered” care. Patient-centered care
Figure 6 Conditional Survival on
the Basis of Device Indication
Kaplan-Meier survival curves for those patients surviving 90 days post-operative
are shown for bridge to transplant (BTT) and destination therapy (DT) indications.
ivation and Validation Cohorts After LVAD Implantd in the Derivation and Validation Cohorts After LVAD Implant
90-Day Survival 1-Yr Survival 2-Yr Survival
86 1% 75 2% 65 2%
96 1% 87 3% 78 4%
84 2% 71 3% 59 4%
71 4% 59 5% 50 5%
87 1% 72 2% 62 3%
92 2% 80 3% 69 4%
88 2% 73 3% 63 4%
74 4% 56 5% 47 5%
86 1% 74 1% 63 2%
94 1% 83 2% 74 3%
86 2% 72 2% 61 3%
73 3% 58 3% 49 4%Figure 5 Kaplan-Meier Survival on the Basis of
Device Indication Stratified by HMRS Group
Survival of patients on the basis of HMRS grouping is shown for BTT (A) and
DT (B) patients in the total HeartMate II sample. Abbreviations as in Figure 4.Survival on the Basis of HMRS in the Total H MII Sample and in the DerTable 5 Survival on the Basis of HMRS in the Total H MII Sample an
HMRS
Threshold HMRS
Derivation cohort (n  583)
Overall — 1.75 (1.18–2.36)
Low risk 1.58 1.05 (0.75–1.31)
Medium risk 1.58–2.48 1.99 (1.75–2.19)
High risk 2.48 3.05 (2.75–3.44)
Validation cohort (n  539)
Overall — 1.71 (1.10–2.31)
Low risk 1.58 1.00 (0.60–1.33)
Medium risk 1.58–2.48 1.94 (1.74–2.20)
High risk 2.48 2.95 (2.70–3.28)
Total sample (N  1,122)
Overall — 1.73 (1.15–2.34)
Low risk 1.58 1.03 (0.68–1.32)
Medium risk 1.58–2.48 1.96 (1.74–2.19)
High risk 2.48 3.01 (2.70–3.35)
11
1
1
1
1
1
1
1
1
2
2
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January 22, 2013:313–21 The HeartMate II Risk Score and LVAD Survivalrequires the process of shared decision making between the
patient and the clinician (20). Studies have shown that
patients want clinicians to openly discuss risks before
surgery (20). Furthermore, patients tend to poorly predict
their own survival. In a study of 122 individuals with
chronic heart failure, 68% of patients over estimated their
survival, and the magnitude of this overestimation was large
(by 40%) (21). Presenting survival estimations with patient-
level data provides LVAD candidates information beyond
that of “average” published LVAD statistics. In elderly
patients and those without a realistic option for transplant,
such information might play even more critically into the
shared decision-making process.
Study limitations. There are several limitations of this
study that must be acknowledged. Even though a large
cohort was studied for purposes of HMRS derivation with
use of internal model validation, the clinical trial patient
population herein is not representative of many non-trial
patients. Thus, further validation of the HMRS in broader
patient populations should be performed. The applicability
of the HMRS to patients undergoing implant of other types
of continuous flow devices is also not known.
Finally, a secondary aim of this analysis was to also
develop a model for predicting long-term survival. Although
the HMRS successfully risk stratified patient survivals
beyond 12 months of LVAD support, only operative sur-
vival, age, and center experience were found to be predictive
of long-term success on LVAD therapy. The study did not
evaluate post-operative management and the advancement
or development of comorbidities during on LVAD out-
comes, which should be included in future analyses.
Conclusions
Risk factors for mortality after HMII continuous flow
LVAD implant in the contemporary LVAD era were
identified with a large patient cohort, and a new risk model
(the HMRS) was prospectively developed and validated.
The HMRS might be useful for patient, family, and
referring provider education, providing patient-level LVAD
mortality risk assessment regardless of BTT or DT indica-
tion. The HMRS also identifies important pre-operative
risk factors that might serve as targets for goal-directed
interventions meant to improve LVAD candidate survival.
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